Abstract
Introduction
The inflammatory bowel disease market is set to grow from $2.9 billion in 2008
to $4.5 billion in 2018 across the seven major markets. While Datamonitor' s
updated forecast will parallel its previous forecast up to 2012, several new
product launches, regional expansion and upgraded brand forecast will help to
sustain growth in the second half of the forecast period.
Scope of this research
- Analysis of the current and future market dynamics in inflammatory bowel
disease across the US, France, Germany, Italy, Spain the UK and Japan
- Assessment of over 25 key marketed inflammatory bowel disease brands and
late stage pipeline products
- Snapshot of inflammatory bowel disease drug sales outside the seven major
markets
- Insight through key opinion leader comments to support conclusions
Research and analysis highlights
Several events, such as new product launches and regional expansion, will
ensure sustained sales growth in the latter part of the forecast period,
overcoming biosimilar entry. Datamonitor' s updated forecast shows sales in the
seven major markets will reach $4.5 billion in 2018.
SONIC trial data shows a u-turn in previous opinion on beginning anti-TNF in
combination with immunosuppressant therapy in biologic- or
immunosuppressant-naive Crohn' s disease patients. Datamonitor expects any
impact from SONIC on clinical practice to emerge slowly within the next 2
years, and will impact across the TNF class.
Cimzia (certolizumab) is better able to compete with Abbott' s Humira
(adalimumab) in Crohn' s disease with its new pre-filled syringe formulation.
Cimzia' s monthly dosing schedule together with its pre-filled syringe and
lower cost will enable the drug to capture almost a quarter of the US anti-TNF
market, in terms of sales, in 2018.
Key reasons to purchase this research
- Understand how new brands Lialda and Apriso will fare against established
market players, such as Asacol and Pentasa
- Assess the impact of the launch of Cimzia' s recent pre-filled syringe and
gauge future dynamics within the anti-TNF class
- Quantify the current and future size of the inflammatory bowel disease
market
| 
View Cart
